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Abstract Soluble factors derived from human CD8+ T-
lymphocytes inhibit HIV-1 replication by suppressing transcrip-
tion from the viral long terminal repeat (LTR), an effect shown 
to be mediated in part by an NFAT-1 enhancer sequence. We 
show here that the CD8+ derived P-chemokines, RANTES, 
M l P l - a , and MIP- ip , known suppressors of HIV-1 replication 
in human peripheral blood mononuclear cells, can suppress 
transcription from the HIV-1 LTR in transient transfection 
assays in cells of the Jurkat (acute T leukemia) line. Surpris-
ingly, the suppression mediated by these P-chemokines persisted 
in the absence of an intact NFAT-1 element, suggesting that 
there are at least two classes of HIV-1 suppressor factors — 
NFAT-1-dependent and NFAT-1-independent factors — pro-
duced by CD8+ T-lymphocytes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
CD8+ T-lymphocytes have been shown to produce soluble 
factor(s) active in suppressing HIV-1 transcription [1-3], 
though the mechanism of action remains to be elucidated. 
Copeland and colleagues [4] showed that this soluble fac-
t o r s - m e d i a t e d suppression of HIV-1 transcription required 
the presence of an intact NFAT-1 element in the L T R of 
HIV-1 . 
Recently, Lusso and colleagues [5] identified several of these 
CD8+-derived HIV-suppressive factors (HIV-SF) as the P-
chemokines R A N T E S , M l P l - a , and M I P - l p . These chemo-
kines have been shown to exert their inhibitory effects when 
added exogenously to cultures of HIV-1 infected T-cell clones 
and primary peripheral blood mononuclear cells (PBMC). 
These two lines of evidence led us to investigate whether the 
observed suppressive effects of R A N T E S , M l P l - a , and MIP-
1P, were effective at the level of transcription, mediated by the 
H I V - L T R NFAT-1 element. 
2. Material and methods 
2.1. Cell culture 
The Jurkat cell line (acute T-cell leukemia) used in this investigation 
was obtained from the American Type Tissue Collection (Rockville, 
MD) and cultured in RPMI-1640 medium (Biofluids Inc., Rockville, 
MD) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Hyclone Laboratories Inc., Gaithersburg, MD), 2 raM L-glu-
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tamine (Quality Biologicals Inc., Gaithersburg, MD), and 100 U/ml 
penicillin+100 ug/ml streptomycin (Quality Biologicals). All cells 
were grown at 37°C with 5% carbon dioxide in a humidified incuba-
tor. 
2.2. Vectors 
The HIV-LTR-CAT constructs were a gift of Dr. Gary Nabel 
(Howard Hughes Medical Institute, University of Michigan) The vec-
tor pLTRCAT contains HIV-1 LTR sequences of the BRU strain to 
position +77 directing chloramphenicol acetyl-transferase (CAT) ex-
pression [4]. The mutant HIV-1 LTR vector has the NFAT-1 IL-2 
homology region altered by site-directed mutagenesis [6]. 
2.3. Transfection 
Cells were transiently transfected with the various reporter gene 
constructs by electroporation, as previously described [7]. Briefly, cells 
were grown to a density of 0.5-1 X 106 cells/ml, harvested, washed, 
and resuspended at 30X106 cells/ml in growth medium. Ten micro-
grams of uncut reporter gene construct along with 10 |ig uncut 
pCMV-(3-galactosidase plasmid (Promega) were added to an 0.5 ml 
of cell suspension in an electroporation cuvette (0.4 cm gap) (Bio-Rad, 
Hercules, CA) and pulsed at 250 V, 960 uFd. Transfected cells 
were resuspended in 30 ml complete medium with or without chemo-
kines and incubated at 37°C, 5% carbon dioxide for 2 days prior to 
harvesting. Expression of CAT was normalized to P-galactosidase 
activity. 
2.4. CAT assays 
CAT assays were performed as described previously [7], Briefly, 10-
30 JJ.1 of cell extract was added to a reaction mixture containing 35 ul 
of 1 M Tris-HCl, pH 7.5, 20 ul of 4 mM acetyl coenzyme A (Phar-
macia, Piscataway, NJ), 5 ul of [14C]chloramphenicol (0.25 uCi/ul; 
New England Nuclear, Boston, MA) and dH20 to 150 ul. After 1-3 
h incubation at 37°C, the [14C]chloramphenicol and acetylated deriv-
atives were extracted with 0.5 ml of ethyl acetate, dried, resuspended 
and applied to a thin layer chromatography sheet (Baker-flex silica gel 
IB, J.T. Baker Inc., Phillipsburg, NJ). Separation of acetylated and 
non-acetylated forms proceeded via a chloroform/methanol (95:5) as-
cending mobile phase followed by autoradiography. The relative in-
tensity of each signal was measured by densitometric scanning (UVP, 
San Gabriel, CA) and analysis (NIH Image software). Experiments 
were performed in duplicate; representative data is presented. 
3. Results and discussion 
Jurkat cells, transiently transfected with the HIV-1 (BRU 
strain) L T R - C A T constructs (Fig. 1) were incubated for 48 h 
following transfection, both in the presence and absence of 
R A N T E S (20 ng/ml), MIPl-cc (100 ng/ml), and M I P - i p (50 
ng/ml). As shown in Fig. 2, reporter gene activity was meas-
ured in the transfected Jurkat cells. In this system, the wild-
type HIV L T R promoted reporter gene activity at ~ 6-fold 
over the background level seen with the promoterless pCAT 
basic construct. In the presence of the P-chemokines, reporter 
gene activity from the wild-type H I V - L T R was reduced to 
nearly one-third of the activity observed in their absence. Dis-
ruption of the N F A T - 1 enhancer element did not alter the 
reporter gene activity promoted by the L T R in the absence 
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Fig. 1. Structure of the wild-type parent HIV-1 LTR and the 
NFAT-1 mutant LTR positioned to direct CAT reporter gene ex-
pression ([4,6]). 
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Fig. 2. Comparison of the effects of p-chemokine treatment, 
RANTES (20 ng/ml), MlPl-a (100 ng/ml), and MIP-ip (50 ng/ml), 
on HIV-1 LTR-CAT construct reporter gene expression. The irrele-
vant control is the tandem promoter, exon 1, and intron of the eosi-
nophil-derived neurotoxin gene placed upstream of CAT ([7]). Ex-
periments were done in duplicate; a representative sample is shown. 
of P-chemokines ( ~ 5.5-fold over background level). Surpris-
ingly, the |3-chemokine combination also maintained tran-
scriptional suppression in the absence of an intact NFAT-1 
enhancer element, reducing reporter gene activity to near 
background levels. As an irrelevant promoter control, tran-
scriptionally active elements of the myeloid eosinophil-derived 
neurotoxin gene [7] were evaluated in this system; only min-
imal chemokine-mediated suppression was observed. 
Our data suggests that the NFAT-1-mediated suppression 
observed by Copeland and colleagues [4] involves HIV-SFs 
other than RANTES, MlPl-a, and MIP-lp. Furthermore, 
our data supports the concept that the P-chemokines interfere 
with HIV-1 replication by transcriptional suppression, a func-
tion that likely coordinates with their role in blocking viral 
entry at the membrane receptor level [8,9]. 
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